• 1
    Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352:1899912.
  • 2
    Krueger G, Ellis CN. Psoriasis – recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53:S94100.
  • 3
    Gisondi P, Girolomoni G, Sampogna F et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalized for psoriasis. Eur J Dermatol 2005; 15:27983.
  • 4
    Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53:573.
  • 5
    Kimball AB, Jacobson C, Weiss S et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6:38392.
  • 6
    Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32:9826.
  • 7
    Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55:82935.
  • 8
    Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8:35563.
  • 9
    Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19:22530.
  • 10
    Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296:173541.
  • 11
    Wakkee M, Thio HB, Prens EP et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190:19.
  • 12
    Malerba M, Gisondi P, Radaeli A et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155:11659.
  • 13
    Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152:597615.
  • 14
    Wilson PW, D’Agostino RB, Parise H et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:306672.
  • 15
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:141528.
  • 16
    Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:264450.
  • 17
    Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:270916.
  • 18
    Taylor W, Gladman D, Helliwell P et al. ; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:266573.
  • 19
    Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157:23844.
  • 20
    Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51:5639.
  • 21
    National Institute of Health. Third report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH publ. no. 01-3670. Bethesda, MD: National Institute of Health, National Heart, Lung and Blood Institute, 2001.
  • 22
    Miccoli R, Bianchi C, Odoguardi L et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005; 15:2504.
  • 23
    Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case–control study. J Invest Dermatol 2005; 125:617.
  • 24
    Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141:152734.
  • 25
    Kimhi O, Caspi D, Bornstein NM et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36:2039.
  • 26
    Chung CP, Oeser A, Raggi P et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52:304553.
  • 27
    Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2:99106.
  • 28
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:53953.
  • 29
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance. Diabet Med 1999; 16:4423.
  • 30
    Meigs JB, Wilson PW, Fox CS et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:290612.
  • 31
    Cowey S, Hardy RW. The metabolic syndrome. A high risk state for cancer? Am J Pathol 2006; 169:150522.
  • 32
    Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 228:270916.
  • 33
    Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56:4562.
  • 34
    Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33:35175.
  • 35
    Du G, Reynolds K, Wu X et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365:1398405.
  • 36
    American Heart Association; National Heart, Lung, and Blood Institute, Grundy SM, Cleeman JI et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005; 13:3227.
  • 37
    Kiortsis DN, Mavridis AK, Vasakos S et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64:7656.
  • 38
    Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR et al. Lipid profile, insulin secretion and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48:8825.
  • 39
    Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54:61421.
  • 40
    Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298:3218.
  • 41
    Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6:77283.
  • 42
    Weiss ST. Obesity: insight into the origins of asthma. Nat Immunol 2005; 6:5379.